Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986315 in advanced solid tumors
NCT04349267Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Jul 2020
- Primary completion
- Aug 2024
- Modality
- Prophylactic Vaccines, Therapeutic Vaccines, Monoclonal Antibodies
- Countries
- 3
01
Overview
A Phase 2 trial of BMS-986315 in squamous cell carcinoma of the head and neck (HNSCC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), sponsored by Bristol Myers Squibb. Started Jul 2020; status: completed.
02
Drugs
BMS-986315
03
Conditions
squamous cell carcinoma of the head and neck (HNSCC)non-small cell lung cancer (NSCLC)renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT04349267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04349267.